MX385575B - Uso de moléculas de ligación a semaforina-4d para el tratamiento de aterosclerosis. - Google Patents
Uso de moléculas de ligación a semaforina-4d para el tratamiento de aterosclerosis.Info
- Publication number
- MX385575B MX385575B MX2016004551A MX2016004551A MX385575B MX 385575 B MX385575 B MX 385575B MX 2016004551 A MX2016004551 A MX 2016004551A MX 2016004551 A MX2016004551 A MX 2016004551A MX 385575 B MX385575 B MX 385575B
- Authority
- MX
- Mexico
- Prior art keywords
- semaphorin
- atherosclerosis
- treatment
- binding molecules
- subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361889421P | 2013-10-10 | 2013-10-10 | |
| PCT/US2014/060129 WO2015054628A1 (en) | 2013-10-10 | 2014-10-10 | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016004551A MX2016004551A (es) | 2016-07-22 |
| MX385575B true MX385575B (es) | 2025-03-18 |
Family
ID=52809873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016004551A MX385575B (es) | 2013-10-10 | 2014-10-10 | Uso de moléculas de ligación a semaforina-4d para el tratamiento de aterosclerosis. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9512224B2 (enExample) |
| EP (1) | EP3054976B1 (enExample) |
| JP (2) | JP6760840B2 (enExample) |
| KR (1) | KR102366682B1 (enExample) |
| CN (1) | CN105848679A (enExample) |
| AU (1) | AU2014331683B2 (enExample) |
| BR (1) | BR112016008010A2 (enExample) |
| CA (1) | CA2926944C (enExample) |
| DK (1) | DK3054976T3 (enExample) |
| EA (1) | EA037551B1 (enExample) |
| ES (1) | ES2821814T3 (enExample) |
| IL (1) | IL244976B (enExample) |
| MX (1) | MX385575B (enExample) |
| NZ (1) | NZ630881A (enExample) |
| PT (1) | PT3054976T (enExample) |
| SG (1) | SG11201602807PA (enExample) |
| WO (1) | WO2015054628A1 (enExample) |
| ZA (1) | ZA201602577B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2427212T3 (enExample) | 2009-05-08 | 2018-01-20 | ||
| CN104168956A (zh) | 2011-10-11 | 2014-11-26 | 瓦西尼斯公司 | 臂板蛋白-4d结合分子用于调节血脑屏障渗透性的用途 |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| BR112015032690B1 (pt) | 2013-06-25 | 2020-03-10 | Vaccinex, Inc. | Uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir o crescimento tumoral e metástase |
| NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| BR112018071686A2 (pt) | 2016-04-22 | 2019-02-19 | Vaccinex, Inc. | exibição de proteínas integrais de membrana em vírions extracelulares envelopados de poxvírus |
| WO2018026715A1 (en) | 2016-08-02 | 2018-02-08 | Vaccinex, Inc. | Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells |
| CN106474559B (zh) * | 2016-11-30 | 2019-07-12 | 西南交通大学 | 一种在心血管植入材料表面构建Sema 4D/Heparin微环境的方法 |
| WO2018156509A1 (en) * | 2017-02-22 | 2018-08-30 | Vaccinex, Inc. | Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases |
| CN106983919B (zh) * | 2017-03-06 | 2019-07-12 | 西南交通大学 | 一种Sema 4D-VEGF涂层的构建方法及应用 |
| CN110636858B (zh) | 2017-05-05 | 2024-03-19 | 瓦西尼斯公司 | 人抗脑信号蛋白4d抗体 |
| CN108499220B (zh) * | 2018-04-25 | 2020-07-31 | 山东纯江环境科技有限公司 | 石墨烯/聚丙烯非织造布过滤网制备方法及其应用 |
| CN109125731B (zh) * | 2018-10-22 | 2019-10-25 | 华中科技大学同济医学院附属协和医院 | Sema4D/PlexinB1抑制剂在制备治疗及预防眼底血管疾病药物中的应用 |
| US20230238135A1 (en) * | 2020-06-19 | 2023-07-27 | The General Hospital Corporation | Near-infrared autofluorescence imaging systems and methods |
| CN117597360A (zh) * | 2020-06-25 | 2024-02-23 | 瓦西尼斯公司 | 脑信号蛋白-4d结合分子在rett综合征治疗中的应用 |
| KR102847091B1 (ko) * | 2022-08-25 | 2025-08-21 | 부산대학교 산학협력단 | 혈관석회화 동반 만성신부전에서 세마포린 4d의 용도 |
| CN116949097B (zh) * | 2023-09-20 | 2023-12-12 | 江苏集萃药康生物科技股份有限公司 | 一种sema4d人源化小鼠模型的构建方法及其应用 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5070192A (en) | 1988-03-23 | 1991-12-03 | The Johns Hopkins University | Cloned human topoisomerase i: cdna expression, and use for autoantibody detection |
| FR2686087A1 (fr) | 1992-01-13 | 1993-07-16 | Inst Nat Sante Rech Med | Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. |
| US5639856A (en) | 1993-09-13 | 1997-06-17 | The Regents Of The University Of California | Semaphorin gene family |
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US6576754B2 (en) | 1995-11-09 | 2003-06-10 | Dana-Farber Cancer Institute | CD100 antigen and uses therefor |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| ES2236634T3 (es) | 1997-04-07 | 2005-07-16 | Genentech, Inc. | Anticuerpos anti-vegf. |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| WO1998046769A1 (en) | 1997-04-11 | 1998-10-22 | Dendreon Corporation | Composition and method for inducing an immune response against tumour-related antigens |
| EP0892047A3 (de) | 1997-07-09 | 2000-03-08 | Hoechst Marion Roussel Deutschland GmbH | Humanes und murines Semaphorin L |
| AU776865B2 (en) | 1998-11-10 | 2004-09-23 | University Of Rochester | T cells specific for target antigens and methods and vaccines based thereon |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| JP3787473B2 (ja) | 1999-11-30 | 2006-06-21 | 独立行政法人科学技術振興機構 | セマフォリン受容体 |
| US6635742B1 (en) | 2000-01-25 | 2003-10-21 | Nuvelo, Inc. | Antibodies specific for semaphorin-like polypeptides |
| IL159177A0 (en) | 2001-06-20 | 2004-06-01 | Prochon Biotech Ltd | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| EP1365018A1 (en) | 2002-05-23 | 2003-11-26 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | CD100 semaphorin in myelination |
| JP4524181B2 (ja) | 2002-05-30 | 2010-08-11 | マクロジェニクス，インコーポレーテッド | Ｃｄ１６ａ結合タンパク質および免疫障害治療のための使用 |
| EP1442749A1 (en) | 2003-01-31 | 2004-08-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system |
| RS20150135A1 (sr) | 2003-05-30 | 2015-08-31 | Genentech Inc. | Tretman sa anti-vegf antitelima |
| RU2006124743A (ru) | 2003-12-11 | 2008-01-20 | Дженентек, Инк. (Us) | СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ИНГИБИРОВАНИЯ ДИМЕРИЗАЦИИ И АКТИВАЦИИ с-Мет |
| US7476724B2 (en) | 2004-08-05 | 2009-01-13 | Genentech, Inc. | Humanized anti-cmet antibodies |
| US20060147449A1 (en) | 2004-11-15 | 2006-07-06 | Brass Lawrence F | Method of using CD100 (or Sema4D) to mediate platelet activation and inflammatory responses |
| EP1871484A2 (en) | 2005-04-07 | 2008-01-02 | Chiron Corporation | Sema4d in cancer diagnosis, detection and treatment |
| JP2007308465A (ja) | 2006-05-15 | 2007-11-29 | Boehringer Ingelheim Internatl Gmbh | 炎症性疾患、自己免疫疾患又は骨吸収異常の治療方法 |
| EP2069404B1 (en) * | 2007-02-14 | 2011-01-05 | Vaccinex, Inc. | Humanized anti-cd100 antibodies |
| WO2009089461A1 (en) | 2008-01-10 | 2009-07-16 | Genentech, Inc. | Plexind1 agonists and their use |
| NO2427212T3 (enExample) | 2009-05-08 | 2018-01-20 | ||
| CA3017298C (en) | 2009-05-15 | 2021-09-28 | Irx Therapeutics, Inc. | Compositions comprising primary cell-derived biologics for enhancing immune responses in patients |
| US8834883B2 (en) | 2010-06-14 | 2014-09-16 | Vaccinex, Inc. | Anti-VEGF antibodies and uses thereof |
| US9447191B2 (en) | 2011-05-13 | 2016-09-20 | National University Corporation Tokyo Medical And Dental University | Osteogenesis promoter |
| CN104168956A (zh) | 2011-10-11 | 2014-11-26 | 瓦西尼斯公司 | 臂板蛋白-4d结合分子用于调节血脑屏障渗透性的用途 |
| US8790652B2 (en) | 2011-12-06 | 2014-07-29 | Vaccinex, Inc. | Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis |
| US9090709B2 (en) | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| BR112015032690B1 (pt) | 2013-06-25 | 2020-03-10 | Vaccinex, Inc. | Uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir o crescimento tumoral e metástase |
| NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
-
2014
- 2014-09-11 NZ NZ630881A patent/NZ630881A/en unknown
- 2014-10-10 US US14/511,679 patent/US9512224B2/en active Active
- 2014-10-10 PT PT148530231T patent/PT3054976T/pt unknown
- 2014-10-10 BR BR112016008010A patent/BR112016008010A2/pt not_active Application Discontinuation
- 2014-10-10 CA CA2926944A patent/CA2926944C/en active Active
- 2014-10-10 ES ES14853023T patent/ES2821814T3/es active Active
- 2014-10-10 CN CN201480067853.5A patent/CN105848679A/zh active Pending
- 2014-10-10 DK DK14853023.1T patent/DK3054976T3/da active
- 2014-10-10 EP EP14853023.1A patent/EP3054976B1/en active Active
- 2014-10-10 SG SG11201602807PA patent/SG11201602807PA/en unknown
- 2014-10-10 EA EA201690728A patent/EA037551B1/ru unknown
- 2014-10-10 MX MX2016004551A patent/MX385575B/es unknown
- 2014-10-10 JP JP2016521774A patent/JP6760840B2/ja active Active
- 2014-10-10 KR KR1020167012123A patent/KR102366682B1/ko active Active
- 2014-10-10 WO PCT/US2014/060129 patent/WO2015054628A1/en not_active Ceased
- 2014-10-10 AU AU2014331683A patent/AU2014331683B2/en active Active
-
2016
- 2016-04-07 IL IL244976A patent/IL244976B/en active IP Right Grant
- 2016-04-15 ZA ZA201602577A patent/ZA201602577B/en unknown
-
2019
- 2019-02-28 JP JP2019035055A patent/JP2019108359A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3054976B1 (en) | 2020-07-08 |
| JP2019108359A (ja) | 2019-07-04 |
| DK3054976T3 (da) | 2020-09-28 |
| WO2015054628A1 (en) | 2015-04-16 |
| PT3054976T (pt) | 2020-08-05 |
| IL244976A0 (en) | 2016-05-31 |
| CN105848679A (zh) | 2016-08-10 |
| KR102366682B1 (ko) | 2022-02-22 |
| BR112016008010A2 (pt) | 2017-09-26 |
| CA2926944A1 (en) | 2015-04-16 |
| EA037551B1 (ru) | 2021-04-13 |
| CA2926944C (en) | 2023-08-08 |
| EP3054976A4 (en) | 2017-05-17 |
| AU2014331683B2 (en) | 2019-07-11 |
| ZA201602577B (en) | 2020-11-25 |
| US20150104462A1 (en) | 2015-04-16 |
| AU2014331683A1 (en) | 2016-04-28 |
| JP6760840B2 (ja) | 2020-09-23 |
| ES2821814T3 (es) | 2021-04-27 |
| EP3054976A1 (en) | 2016-08-17 |
| IL244976B (en) | 2020-07-30 |
| EA201690728A1 (ru) | 2016-08-31 |
| KR20160062167A (ko) | 2016-06-01 |
| US9512224B2 (en) | 2016-12-06 |
| SG11201602807PA (en) | 2016-05-30 |
| MX2016004551A (es) | 2016-07-22 |
| NZ630881A (en) | 2016-03-31 |
| JP2016539089A (ja) | 2016-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX385575B (es) | Uso de moléculas de ligación a semaforina-4d para el tratamiento de aterosclerosis. | |
| CY1122278T1 (el) | Αντι il-36r αντισωματα | |
| CO2018000104A2 (es) | Moléculas de anticuerpo que se unen a cd22 | |
| CY1121517T1 (el) | Μη φουκοζυλιωμενα αντισωματα enanti-fgfr2iiib | |
| BR112016010169A2 (pt) | anticorpos anticlaudina e métodos de uso | |
| MX341076B (es) | Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados. | |
| MX2016005050A (es) | Uso de moleculas de union a semaforina-4d para el tratamiento de trastornos neurodegenarativos. | |
| CR20140529A (es) | Anticuerpos e inmunoconjugados contra ly6e y métodos de uso | |
| BR112016013048A2 (pt) | anticorpos anti-dpep3 e métodos de uso | |
| CY1119042T1 (el) | Υποκατεστημενες ξανθινες και μεθοδοι χρησης αυτων | |
| EA201391507A1 (ru) | АНТИТЕЛА ПРОТИВ c-Kit И ИХ ПРИМЕНЕНИЕ | |
| CL2016000468A1 (es) | Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso. | |
| EA201590174A1 (ru) | Иммуноконъюгаты, содержащие анти-cd22 антитела | |
| EA201890320A1 (ru) | Молекулы антител, которые связывают cd79 | |
| JOP20200016B1 (ar) | أجسام مضادة لـ cd137 | |
| BR112015003757A2 (pt) | anticorpos e vacinas para uso no tratamento de cânceres de ror1 e inibição de metástase | |
| EA201890754A1 (ru) | Соединения и способы их применения | |
| BR112014020826A2 (pt) | moduladores e métodos de uso | |
| CL2014000543A1 (es) | Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer. | |
| EA201401077A1 (ru) | Биспецифические антитела к человеческому tweak и человеческому il17 и их применения | |
| BR112015025347A2 (pt) | 2-acetil-nafto [2-3-b] furan-4,9-diona para uso no tratamento do câncer | |
| EA201490778A1 (ru) | АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ПРИМЕНЕНИЯ | |
| BR112016004245A2 (pt) | moduladores de sez6 e métodos de uso | |
| CL2014003339A1 (es) | Anticuerpo humanizado anti-trka con propiedades inhibitorias mejoradas; composición que lo comprende; y uso para tratar el dolor. | |
| MX381278B (es) | Composición para la estimulación ovárica controlada. |